PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1485253
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1485253
Upstream Bioprocessing Market - By Product, Usage Mode, Mode, Application, End-user - Global Forecast, 2024 - 2032
Upstream Bioprocessing Market size is projected to expand at 9.7% CAGR from 2024 to 2032. Rapid advancements in biotechnology and genetic engineering are driving the development of novel biopharmaceuticals, subsequently accelerating the demand for upstream bioprocessing solutions. The growing prevalence of chronic diseases along the rising need for effective treatments is boosting the production of biologics and making way for the higher adoption of bioprocessing technologies.
The influx of favorable government initiatives and investments in biotechnology R&D is driving innovations in the upstream bioprocessing industry. To cite an instance, in September 2023, Sartorius and Repligen Corporation introduced an integrated bioreactor system, combining the former's Biostat Stirred-Tank Reactor (STR) with Repligen's XCell Alternating Tangential Flow (ATF) technology.
The expansion of contract manufacturing organizations (CMOs) and outsourcing of bioprocessing activities by pharmaceutical companies is also increasing the adoption of upstream bioprocessing. Moreover, technological innovations in cell culture techniques and single-use bioreactors are leading to enhanced efficiency and scalability, further driving the industry growth.
The upstream bioprocessing market is segregated into product, usage mode, mode, application, end-user, and region.
In terms of product, the market value from the cell culture products segment is anticipated to rise at 12.5% growth rate between 2024 and 2032. The increasing demand for biopharmaceuticals is fueling the need for cell culture products for protein expression and production. Significant advancements in cell culture techniques, like single-use bioreactors are improving efficiency and scalability. The expansion of biotechnology and pharmaceutical sector will also boost the demand for cell culture products.
With respect to application, the upstream bioprocessing industry from the vaccine production segment will expand at 10.8% CAGR until 2032. The rising global demand for vaccines to combat infectious diseases is driving the need for efficient bioprocessing solutions. The advancements in biotechnology are facilitating the development of novel vaccine candidates and increasing the appeal for upstream bioprocessing technologies. The rollout of government funding for vaccine R&D will further benefit the segment growth.
Regionally, the Asia Pacific upstream bioprocessing market will record 12.1% CAGR between 2024 and 2032, on account of the increasing investments in biotechnology R&D by government and private organizations. The growing prevalence of chronic diseases is fueling the demand for biopharmaceuticals and driving the need for upstream bioprocessing solutions. The presence of a large pool of skilled labor and lower manufacturing costs are attracting biotechnology companies, further driving the regional industry progression.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Base estimates & calculations
- 1.3 Data collection
- 1.4 Forecast parameters
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing adoption of single-use bioprocessing systems
- 3.2.1.2 Rising implementation of process analytical technology (PAT)
- 3.2.1.3 Increasing demand for biopharmaceuticals
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High capital costs
- 3.2.2.2 Technical and operational challenges related to upstream bioprocessing
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
- 3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Bioreactors/Fermenters
- 5.3 Cell culture products
- 5.4 Filters
- 5.5 Bioreactor accessories
- 5.6 Bags & containers
- 5.7 Other products
Chapter 6 Market Estimates and Forecast, By Usage Mode, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Multi-use
- 6.3 Single-use
Chapter 7 Market Estimates and Forecast, By Mode, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 In-house
- 7.3 Outsourced
Chapter 8 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Monoclonal antibody production
- 8.3 Vaccine production
- 8.4 Cell and gene therapy production
- 8.5 Other applications
Chapter 9 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 Biopharmaceutical companies
- 9.3 CDMOs and CROs
- 9.4 Research and academic institutes
Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 10.1 Key trends
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
- 10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
- 10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa
Chapter 11 Company Profiles
- 11.1 Applikon Biotechnology
- 11.2 Boehringer Ingelheim GmbH
- 11.3 CellGenix GmbH
- 11.4 Corning, Inc.
- 11.5 Danaher Corporation (Cytvia)
- 11.6 Eppendorf AG
- 11.7 Merck KGaA
- 11.8 PBS Biotech, Inc.
- 11.9 Sartorius AG
- 11.10 Thermo Fisher Scientific Inc.
